PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).
Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D
Pemvidutide (2.4 mg), an investigational GLP-1/glucagon dual receptor agonist, helped people with obesity achieve an average 15.6% weight loss after 48 weeks in the phase